Table 2.
Factors Driving Growth of Pharmaceutical Expenditures in Clinics and Nonfederal Hospitals in 2020, by Product Categorya
| Product Category | Clinics | Nonfederal Hospitals | ||||||
|---|---|---|---|---|---|---|---|---|
| Total Percent Growth | Percent Growth Due to Factor | Total Percent Growth | Percent Growth Due to Factor | |||||
| New Products | Price | Volume and Mix | New Products | Price | Volume and Mix | |||
| All products | 8.1 | 2.3 | –1.5 | 7.3 | –4.6 | 4.6 | 0.5 | –9.7 |
| Injectables | 7.6 | 2.8 | –1.6 | 6.4 | –4.9 | 5.7 | 0.9 | –11.5 |
| Branded | 8.4 | 2.8 | –1.7 | 7.3 | –6.0 | 7.2 | 1.3 | –14.5 |
| Generic | –2.7 | 4.0 | –4.2 | –2.5 | –5.0 | 2.4 | –3.8 | –3.6 |
| Branded generic | –0.1 | 0.5 | 1.4 | –2.0 | 2.5 | 0.2 | 3.9 | –1.6 |
| Noninjectables | 10.9 | 0.9 | –1.1 | 11.1 | –3.7 | 1.0 | –0.9 | –3.8 |
| Branded | 13.9 | 0.5 | –0.1 | 13.5 | 0.6 | 0.2 | 0.2 | 0.2 |
| Generic | –5.8 | 4.4 | –10.8 | 0.6 | –5.1 | 3.7 | –3.3 | –5.5 |
| Branded generic | 5.3 | 0.2 | 2.8 | 2.3 | –12.6 | 0.1 | –1.4 | –11.3 |
aTotal growth comprised growth attributable to 3 factors: (1) new products (products that were not on the market in the previous year), primarily newly approved and marketed agents; (2) price (changes in the unit cost of drugs that were on the market in the previous year); and (3) volume and mix (changes in volume of utilization of existing products or changes in utilization patterns [eg, a shift from one product to another, as when prescribing moves from branded to generic products]).